VT
GMAB icon

Vise Technologies’s Genmab GMAB Stock Holding History

Vise Technologies’s Portfolio GMAB Stock Details GMAB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$510K Hold
16,544
– – 0.01% 856
2025
Q4 		$510K Buy
16,544
+2,656
+19% +$82.8K 0.01% 861
2025
Q3 		$426K Sell
13,888
-570
-4% -$13.9K 0.02% 739
2025
Q2 		$299K Buy
+14,458
New +$297K 0.01% 840
2024
Q4 		$269K Buy
12,892
+3,794
+42% +$83.4K 0.02% 641
2024
Q3 		$222K Buy
+9,098
New +$243K 0.03% 543

Other funds holding GMAB

OAG
Orbis Allan Gray Hamilton, Bermuda $23.7B AUM 65.43% 1-Year Est. Return
AllianceBernstein
AllianceBernstein Nashville, Tennessee $309B AUM 23.92% 1-Year Est. Return
PBA
Paradigm Biocapital Advisors New York $4.89B AUM 251.12% 1-Year Est. Return
Arrowstreet Capital
Arrowstreet Capital Boston, Massachusetts $185B AUM 39.58% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return
HL
Harding Loevner Bridgewater, New Jersey $9.72B AUM 22.38% 1-Year Est. Return
DM
Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return
First Trust Advisors
First Trust Advisors Wheaton, Illinois $140B AUM 27.84% 1-Year Est. Return

Vise Technologies's GMAB Position: Q1 2026 in Review

Vise Technologies held its Genmab (GMAB) position steady in Q1 2026 at 16,544 shares worth $510K. The position accounts for 0.01% of the portfolio, ranked #856.

Vise Technologies first reported a position in GMAB in Q3 2024 and has held it in 6 quarters since. 272 funds tracked by Wall St. Rank hold GMAB as of Q1 2026.

  • Vise Technologies held 16,544 shares of Genmab worth $510K as of Q1 2026.
  • Vise Technologies left its Genmab share count unchanged in Q1 2026.
  • Genmab made up 0.01% of Vise Technologies's portfolio in Q1 2026, its #856 holding.
  • Vise Technologies first reported a position in Genmab in Q3 2024 and has held it in 6 quarters since.
  • 272 funds tracked by Wall St. Rank held Genmab as of Q1 2026.

Based on Vise Technologies's 13F filing for Q1 2026, filed 21 Apr 2026.